224 related articles for article (PubMed ID: 23241501)
21. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Agelaki S; Syrigos K; Christophylakis C; Boukovinas J; Varthalitis J; Pavlakou G; Athanasiadis A; Kouroussis C; Vardakis N; Maltezakis G; Milaki G; Georgoulias V;
Oncology; 2004; 66(3):192-6. PubMed ID: 15218309
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
[TBL] [Abstract][Full Text] [Related]
23. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
Rocha Lima CM; Sherman CA; Brescia FJ; Brunson CY; Green MR
Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):46-51. PubMed ID: 11301841
[TBL] [Abstract][Full Text] [Related]
24. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
25. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
[TBL] [Abstract][Full Text] [Related]
26. [Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies].
Muneoka K; Shirai Y; Sasaki M; Wakai T; Sakata J; Toshima M; Hatakeyama K
Gan To Kagaku Ryoho; 2008 Jan; 35(1):61-4. PubMed ID: 18195529
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
[TBL] [Abstract][Full Text] [Related]
28. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
30. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
33. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Rocha-Lima CM; Herndon JE; Lee ME; Atkins JN; Mauer A; Vokes E; Green MR;
Ann Oncol; 2007 Feb; 18(2):331-7. PubMed ID: 17065590
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Kurata T; Yamamoto N; Komiya T; Tsurutani J; Miyazaki M; Tamura K; Takeda K; Nakagawa K; Fukuoka M
Jpn J Clin Oncol; 2010 Oct; 40(10):992-4. PubMed ID: 20522445
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
Sohal DP; Mykulowycz K; Uehara T; Teitelbaum UR; Damjanov N; Giantonio BJ; Carberry M; Wissel P; Jacobs-Small M; O'Dwyer PJ; Sepulveda A; Sun W
Ann Oncol; 2013 Dec; 24(12):3061-5. PubMed ID: 24146220
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
38. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Endlicher E; Schnoy E; Troppmann M; Rogler G; Messmann H; Klebl F; Gelbmann C; Kullmann F
Digestion; 2016; 93(3):229-33. PubMed ID: 27089254
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
[TBL] [Abstract][Full Text] [Related]
40. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
